Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty

Basit Öğe Kaydı
dc.contributor.authorKayikcioglu, M
dc.contributor.authorCan, L
dc.contributor.authorKultursay, H
dc.contributor.authorPayzin, S
dc.contributor.authorTurkoglu, C
dc.date.accessioned2019-10-27T18:44:00Z
dc.date.available2019-10-27T18:44:00Z
dc.date.issued2002
dc.departmentEge Üniversitesien_US
dc.description49th Annual Scientific Session of the American-College-of-Cardiology -- MAR 12-15, 2000 -- ANAHEIM, CAen_US
dc.description.abstractAim - To determine whether statin therapy initiated early in acute myocardial infarction together with thrombolytic therapy in patients with acute myocardial infarction results in clinical benefit through early plaque stabilization. Methods and results - The study population consisted of 77 patients who underwent coronary balloon angioplasty of the infarct-related artery during the first month of acute myocardial infarction. These patients belonged to the cohort of the Pravastatin Turkish Trial (PTT). Forty of them were assigned randomly to have immediate pravastatin (40 mg/day) therapy adjunctive to thrombolytic therapy regardless of serum lipid levels and received statin treatment throughout the study. Lipid levels were determined immediately after admission and before angioplasty and at the end of 6 months. Patients were re-evaluated clinically and angiographically for cardiovascular adverse events and restenosis after a 6-month follow-up period. The baseline angiographic and clinical characteristics of the two groups were similar. The incidence of angina was significantly lower in the pravastatin group (30.0%, 12 patients) compared to the control group (59.5%, 22 patients) (p = 0.018). The cumulative major adverse cardiac events in the pravastatin group were significantly lower when compared to the control group (32.5% vs. 75.6%, p = 0.0001). Conclusions - Early initiation of pravastatin therapy immediately after an acute myocardial infarction significantly decreased the frequency of major cardiac adverse events. Such early potential clinical benefits further strengthen the rationale for starting statin treatment as soon as possible after acute coronary events particularly in patients in whom invasive intervention is planned.en_US
dc.description.sponsorshipAmer Coll Cardiolen_US
dc.identifier.doi10.2143/AC.57.4.2005430en_US
dc.identifier.endpage302en_US
dc.identifier.issn0001-5385
dc.identifier.issn1784-973X
dc.identifier.issue4en_US
dc.identifier.pmid12222700en_US
dc.identifier.startpage295en_US
dc.identifier.urihttps://doi.org/10.2143/AC.57.4.2005430
dc.identifier.urihttps://hdl.handle.net/11454/37268
dc.identifier.volume57en_US
dc.identifier.wosWOS:000177629400011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofActa Cardiologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectacute myocardial infarctionen_US
dc.subjectstatinsen_US
dc.subjectthrombolytic therapyen_US
dc.titleEarly use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplastyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu